Wednesday, January 05, 2022 9:21:57 AM
William A. Hartman, Chairman, President, and CEO, stated, "Halberd's patented extracorporeal technologies permit us to advance the potential treatment of neurodegenerative diseases beyond anybody else in the industry. The magnitude of the health problems associated with neurodegenerative diseases in the USA alone is far larger than is generally known:
PTSD/CTE-24.5 million (men at 6% and women at 8% of population per the National Center for PTSD)
Alzheimer's Disease-6.2 million (40 million worldwide)
Parkinson's Disease-1.0 million
Multiple Sclerosis-400,000
Lou Gehrig's Disease-30,000
Huntington's Disease-30,000
Epilepsy-3.4 million
Total-35.6 million
"Halberd successfully achieved proof-of-concept that the "Top Ten" disease antigens, inflammatory cytokines, and excitatory neurotransmitter associated with these diseases can be safely removed from cerebral spinal fluid using our patented extracorporeal process. We expect to complete the eradication of the of last of these pathogens from cerebral spinal fluid in our laboratory and engage in in-vivo advanced experimentations involving animal studies soon. Completion of these studies will advance Halberd's technology one step closer toward a successful treatment regimen for a suffering world."
HALB $$$
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM